Photoallergy & Phototoxicity
Adverse skin reactions caused by light acting together with a chemical (chemical-induced photosensitivity) fall into two entirely separate mechanisms: phototoxicity and photoallergy. Both require two things at the same time: a light-absorbing substance (a photosensitizer), either a systemic drug or something applied to the skin, and electromagnetic radiation, mainly UVA (320–400 nm) and less often UVB or visible light.
Phototoxicity
- Chemical and cellular mechanism: After absorbing photon energy from UV light, the photosensitizer is raised to a high-energy state. It then reacts directly with molecular oxygen to generate reactive oxygen species (ROS) such as singlet oxygen and superoxide radicals, or directly damages DNA (single- or double-strand breaks) and cell membrane lipids.
- Key features: The immune system is not involved. It will occur in 100% of people given a high enough dose of the drug and of UV light, and it flares on the very first exposure.
- Histopathology: Scattered or full-thickness necrosis of epidermal keratinocytes (keratinocyte necrosis / sunburn cells), edema of the upper dermis, extravasated red blood cells and a light neutrophilic infiltrate.
Photoallergy
- Immunological mechanism: UV light chemically converts the photosensitizer (or one of its metabolites) into a hapten. The hapten binds covalently to the body's own proteins, creating a complete photoallergen.
- Cellular activation: Epidermal Langerhans cells take up the antigen and present it to CD4+ and CD8+ T cells in the regional lymph nodes. On re-exposure to the drug and light, memory T cells travel to the skin and release cytokines (IFN-gamma, IL-2), producing an eczema-like allergic inflammation.
- Histopathology: Epidermal spongiosis, a dense lymphocytic infiltrate around the superficial dermal vessels and edema of the papillary dermis. The picture resembles ordinary allergic contact dermatitis.
Telling phototoxicity and photoallergy apart is the deciding step for prognosis and treatment choice. Phototoxicity usually settles once the drug dose is adjusted, while photoallergy can persist and evolve into chronic photosensitivity dermatitis (persistent light reactor / CAD) even after the trigger has been stopped completely.
Clinical Features and Common Trigger Drugs
Clinical Forms of Phototoxicity
- Acute sunburn-like reaction (sunburn-like response): Within hours of sun exposure, exposed skin turns bright red, burns intensely and swells, with tense, clear fluid-filled blisters. Common culprits are doxycycline, tetracycline, vemurafenib and hydrochlorothiazide.
- Light-induced nail separation (photo-onycholysis): The fingernail or toenail lifts off the nail bed at its free edge after sun exposure while taking doxycycline or a fluoroquinolone. Splinter hemorrhages may also appear.
- Chronic blue-gray pigmentation: Amiodarone (an antiarrhythmic) causes lipofuscin–drug complexes to build up in facial skin, giving a characteristic slate-gray pigmentation.
- Pseudoporphyria: Tense, fragile blisters on the backs of the hands that break and leave atrophic scars, caused by naproxen or ketoprofen. Under the microscope it looks like porphyria cutanea tarda, but porphyrin tests are completely normal.
Clinical Forms of Photoallergy
- Acute or chronic eczema-like rash (eczematous eruption): Red papules and tiny vesicles with intense itching.
- Spread beyond exposed skin: The rash does not stay in sun-exposed areas but spreads to covered skin (unexposed areas). This is the key clinical clue that separates it from phototoxicity.
- Common triggers: Sunscreens containing oxybenzone or octocrylene, topical pain relievers (ketoprofen, diclofenac) and fragrances (musk ambrette, 6-methylcoumarin).
Phototoxicity vs Photoallergy: Side-by-Side Comparison
| Feature | Phototoxicity | Photoallergy |
|---|---|---|
| Mechanism | Non-immune (direct cell toxicity / ROS) | Type IV delayed hypersensitivity (mainly T-cell mediated) |
| Frequency in the population | Very high (occurs in 100% of people given a sufficient dose) | Low (only in sensitized individuals) |
| Dose dependence | Closely tied to both drug dose and UV dose | Dose-independent (even tiny amounts can trigger it) |
| Onset | Acute (minutes to hours), from the first exposure | 24–72 hours (after a 7–14-day sensitization period) |
| Lesion type | SUNBURN-like (redness, blisters, hyperpigmentation) | ECZEMA-like (itchy papules, spongiosis, tiny vesicles) |
| Borders | Strictly limited to sun-exposed skin (sharp borders) | Spreads to covered skin (ill-defined borders) |
| Photopatch test | Negative, or irritant reaction only | POSITIVE (+) at the UVA-irradiated site |
Diagnosis, Photopatch Testing and Treatment at Haute-Derma
At Haute-Derma, patients with a suspected light-and-drug or light-and-chemical skin reaction are managed under our photoallergen identification and skin recovery protocol (Haute-Derma Photo-Drug Protocol):
Photopatch Testing
- Indication: Required for every suspected case of photoallergy or reaction to a sunscreen or topical medication.
- Technique:
- Two identical sets of allergens (a standard photopatch series including UV filters, NSAIDs, fragrances and preservatives) are applied side by side on sun-protected skin of the back.
- After 48 hours: Both sets are removed. One side of the back is kept fully shielded from light; the other side receives UVA at a dose below the threshold for redness.
- Readings at 48 hours (right after UVA), 72 hours and 96 hours:
- Phototoxicity: redness appears right after UVA exposure and fades by 72 hours.
- Photoallergy: an itchy eczematous reaction that intensifies at 72–96 hours only on the UVA-exposed side (the shielded side stays negative).
- Ordinary contact allergy: the same inflammatory reaction appears on both sides (irradiated and shielded).
Acute Management
- Stop the suspected drug or chemical immediately: Switch to an alternative without photosensitizing potential (for example, azithromycin instead of doxycycline, or paracetamol instead of ketoprofen).
- Controlling the sunburn-like or eczematous reaction:
- Cool compresses with normal saline or 5% aluminum acetate solution for 15–20 minutes, 3 times a day.
- Topical corticosteroids: clobetasol propionate 0.05% or betamethasone dipropionate 0.05% for 5–7 days to quickly reduce swelling and blistering.
- Systemic corticosteroids: prednisolone 0.5–1 mg/kg/day for 3–5 days for phototoxic reactions with widespread blistering or severe swollen redness.
Barrier Repair and Long-Term Management
- Low-level light therapy (LLLT, 630 nm) to stimulate regeneration of the damaged epidermis without adding heat or further photochemical injury.
- Repairing the skin's lipid barrier with a moisturizer in the standard ceramide : cholesterol : free fatty acid ratio (3:1:1).
- Switching to a 100% mineral (physical) sunscreen with micronized zinc oxide or titanium dioxide, free of chemical filters (oxybenzone, avobenzone, octocrylene) and fragrance.
